Natco Pharma Ltd.

Natco Pharma is currently trading at Rs. 975.70, up by 35.10 points or 3.73% from its previous closing of Rs. 940.60 on the BSE.

The scrip opened at Rs. 950.00 and has touched a high and low of Rs. 981.95 and Rs. 950.00 respectively. So far 6505 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1188.95 on 24-May-2021 and a 52 week low of Rs. 732.00 on 09-Sep-2020.

Last one week high and low of the scrip stood at Rs. 981.95 and Rs. 923.00 respectively. The current market cap of the company is Rs. 17777.94 crore.

The promoters holding in the company stood at 48.87%, while Institutions and Non-Institutions held 29.94% and 21.19% respectively.

Natco Pharma’s subsidiary -- Natco Pharma (Canada) Inc. has launched NAT-LENALIDOMIDE Capsules, the first generic alternative to Revlimid to be approved by Health Canada.

NAT-LENADLIDOMIDE is used in combination with dexamethasone for the treatment of multiple myeloma in patients who are not eligible for stem cell transplant. NAT-LENALIDOMIDE is also indicated for treatment of transfusion-dependent anemia due to Low- or Intermediate-1-risk myelodysplastic syndromes associated with a deletion of 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.